X-Change, a company specializing in natural cannabinoid-based food and cosmetic products, has appointed former GlaxoSmithKline executive Dr. Dorothy Bray, Ph.D., president. Bray has experience in drug development, including specific expertise in plant-based research in medicine and nutrition.

Bray was global director of HIV Research and senior clinical program head of HIV and opportunistic infections at GSK. Bray also served as senior medical strategy head, international medical affairs and as principal clinical research scientist at antivirals, U.K. and U.S.  She was head of scientific business development of the medical research council clinical trials unit in the U.K.

Bray received a fellowship from the Winston Churchill Memorial Trust in the U.K. to study medicinal plants in Africa, a research grant from the Sir Halley Stewart Trust to study natural products and a fellowship from the Royal Society to study immune system response to natural products. Bray also served as a research fellow at the London School of Hygiene and Tropical Medicine, where she studied the chemical compounds and selected molecules of medicinal plants in collaboration with the World Health Organization (WHO) Tropical Diseases Program and the University of Geneva.